Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Cancer is a leading cause of death globally, with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations driving a significant proportion of solid tumors.
• KRAS mutations, prevalent in lung, pancreatic, and colon cancers, are associated with poor prognosis and reduced survival.
• Historically, KRAS has been considered

Purpose of the Study:

• To provide an overview of KRAS mutation characteristics in solid tumors.
• To highlight advancements in understanding the KRAS immune microenvironment and developing KRAS-driven mouse models.
• To review recent progress in targeted therapeutic approaches for KRAS-mutated cancers.

Main Methods:

• Literature review of biochemical and technological advances in targeted cancer therapy.
• Analysis of research on the tumor immune microenvironment in KRAS-driven cancers.
• Examination of preclinical models, including KRAS-driven mice.
• Synthesis of current therapeutic strategies targeting specific KRAS mutations.

Main Results:

• Significant breakthroughs in targeted therapies for KRAS-mutated cancers have emerged in the last decade.
• Understanding of KRAS biology and its role in cancer development has advanced considerably.
• Novel therapeutic strategies are being explored to overcome the challenges of targeting KRAS.

Conclusions:

• Targeted therapies represent a paradigm shift in treating KRAS-mutated cancers.
• Continued research into the immune microenvironment, preclinical models, and specific KRAS mutant-targeted therapies is crucial.
• Comprehensive understanding of KRAS signaling and therapeutic developments holds potential for improved patient outcomes in solid tumors.